Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.…
Bullfrog AI Holdings Inc. (BFRG) Reports Q3 Loss, Lags Revenue Estimates
Bullfrog AI Holdings (NASDAQ: BFRG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.3556 USD on 20 November 2026, down 67.7% over 52 weeks. Its 52-week range is 0.3500 USD to 1.960 USD: the price is 81.9% below the high and 1.6% above the low.
Its market capitalisation is 6.65M USD.
Bullfrog AI Holdings reports return on equity of -304.2% and revenue up 547.6% year over year.
It holds more cash than debt, a net cash position of 6.83M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.